Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K-rhein is a tri-potassium salt of rhein, an anthraquinone compound derived from various medicinal herbs such as *Rheum palmatum L.* and *Aloe barbadensis Miller*. It was developed to enhance the poor water solubility of its active component, rhein. K-rhein specifically functions as an inhibitor of CD38 enzymatic activity. Rhein, the active ingredient, exhibits a broad spectrum of pharmacological activities, including anti-inflammatory, anticancer, antidiabetic, hepatoprotective, nephroprotective, antioxidant, and antifibrotic effects. Its mechanism involves modulating various signaling pathways such as NF-κB, PI3K/Akt, MAPK, p53, and HIF-1, and it can induce apoptosis in cancer cells. K-rhein has demonstrated potential in inhibiting glioma progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on K-rhein.